Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) rose 9.1% on Friday . The company traded as high as $4.90 and last traded at $4.90. Approximately 1,440,608 shares changed hands during trading, a decline of 40% from the average daily volume of 2,413,346 shares. The stock had previously closed at $4.49.
Wall Street Analyst Weigh In
A number of brokerages have commented on HUMA. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a report on Thursday, November 21st. Benchmark reaffirmed a "buy" rating and set a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective on shares of Humacyte in a research note on Wednesday, November 13th. EF Hutton Acquisition Co. I raised shares of Humacyte to a "strong-buy" rating in a report on Monday, September 9th. Finally, TD Cowen reiterated a "buy" rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $13.00.
Read Our Latest Analysis on HUMA
Humacyte Price Performance
The company's 50-day moving average is $5.11 and its 200-day moving average is $6.08. The firm has a market cap of $607.90 million, a price-to-earnings ratio of -3.60 and a beta of 1.38. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61.
Insider Buying and Selling at Humacyte
In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the business's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares of the company's stock, valued at approximately $10,743,521.28. The trade was a 25.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kathleen Sebelius sold 5,182 shares of the firm's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the sale, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. The trade was a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,662,886 shares of company stock valued at $7,489,538. 11.20% of the stock is currently owned by corporate insiders.
Institutional Trading of Humacyte
A number of hedge funds have recently added to or reduced their stakes in HUMA. State Street Corp increased its holdings in shares of Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company's stock worth $25,917,000 after buying an additional 1,895,529 shares in the last quarter. Millennium Management LLC increased its holdings in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company's stock worth $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Vanguard Group Inc. raised its position in Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company's stock valued at $12,501,000 after purchasing an additional 896,415 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company's stock valued at $2,881,000 after purchasing an additional 524,600 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company's stock worth $2,226,000 after purchasing an additional 450,031 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company's stock.
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
